Should I open or buy a Medi-Weightloss franchise in 2027?

The outcome you should expect

Set your expectations against the two things that actually determine a medical weight-loss clinic's trajectory: how fast you fill exam-room capacity, and whether your prescriber cost scales with that fill rate or sits as dead weight.

A realistic base case for a single new clinic opened in a suburban market with 100,000+ people in the protected territory looks like this. Months 1–4 after opening you are running a patient-acquisition deficit — you are paying rent, a medical director retainer, an NP or nurse salary, and front-desk labor against maybe 40–90 active patients. Months 5–12 you climb toward 150–250 active patients if your marketing works. By month 18–24, a healthy unit is at 250–400 active patients and grossing somewhere in the $700,000–$2,000,000 band, with owner earnings of roughly $120,000–$350,000 depending on whether you are absentee (paying a full manager) or working the business.

The GLP-1 protocol changes the shape of that ramp materially. A patient on a supervised semaglutide or tirzepatide program returns every 4–6 weeks for weight checks, vitals, bloodwork review, and dose titration. That is 8–12 billable touchpoints per year instead of the 3–5 a traditional coaching-and-supplements patient generates. Annual revenue per GLP-1 patient runs roughly $3,000–$7,000 versus $800–$1,500 for a non-medication patient. You need fewer bodies through the door to hit the same gross, which is the single most important economic fact about this franchise in 2027.

The outcome you should NOT expect is a passive investment. This is not a laundromat or a vending route. You are operating a healthcare business with a prescriber of record, controlled-substance-adjacent protocols in some states, state medical board oversight, HIPAA obligations, and a labor pool (physicians, NPs, PAs) that has more options than you do. If you want a franchise you can visit twice a week, the medical weight-loss category is the wrong shelf.

The realistic downside case is worth naming plainly: you sign the franchise agreement, sign a 5-year lease, spend $120,000 on build-out, and then spend four months failing to recruit a medical director. You burn $30,000–$50,000 in rent and carrying costs on an empty shell, open late into a market where two competitors have already captured the early-adopter GLP-1 patients, and spend year one at $350,000–$500,000 gross — which does not clear owner comp after a prescriber salary. That failure mode is not exotic; it is the most common one in this category.

What drives that outcome

Four variables move the needle, and they are not equally weighted. Ranked by impact on a 2027 unit:

Prescriber cost as a percentage of gross. This is the dominant line item and the one most under your control at the structuring stage. A part-time medical director in a suburban market commands roughly $60,000–$120,000 annually; in a competitive metro it runs $100,000–$180,000. A full-time employed physician is $180,000–$250,000 plus benefits. If your clinic grosses $800,000 and you are carrying a $200,000 physician, your prescriber load is 25% of gross before you have paid rent, royalty, or front-desk staff. If you instead run an NP at $90,000–$130,000 under a collaborative agreement with a $30,000–$60,000 remote supervising physician, the same clinic carries 15–20%. That delta of 5–10 points of gross is the difference between $80,000 and $160,000 of owner earnings.

GLP-1 mix. The percentage of your patient panel on a medication protocol drives revenue per patient by a factor of 3–5x. Clinics running 55–70% of new patients on a GLP-1 protocol hit revenue targets with roughly half the patient count of a coaching-heavy panel.

Territory density. Exclusive territory in the FDD is typically defined by a radius (1 mile urban, 2–3 miles suburban, up to 5 miles rural) or a population count around 100,000. Exclusivity protects you from another Medi-Weightloss unit, not from a med-spa, a telehealth prescriber, or a primary-care practice that added weight management last quarter.

Ramp speed on patient acquisition. Every month you spend below break-even patient count is a month of full fixed cost against partial revenue. Cutting your ramp from 12 months to 7 is worth more than any single cost cut you can make.

Benchmarks and realistic ranges

Work from the 2026 FDD as filed, not from franchise-portal summaries. The figures below are the ranges you should be testing against Item 7 and Item 19 when you get the document.

Initial investment. Total Item 7 lands in the neighborhood of $200,000–$450,000. The franchise fee itself is around $40,000. Build-out and leasehold improvements are the widest swing: $80,000–$240,000 depending almost entirely on whether the space was previously medical. A former dental or primary-care suite with existing plumbing, sinks in each room, and medical-grade HVAC can cut that number in half versus raw retail shell. Equipment and technology (exam tables, body-composition analyzers, scales, phlebotomy setup, EMR licensing) runs $40,000–$110,000. Signage and brand-prescribed decor is $12,000–$40,000. Opening inventory and medical supplies is $15,000–$45,000. Initial marketing to seed patient acquisition is $25,000–$60,000 — do not shortcut this line. Training and travel for you plus clinical staff is $10,000–$28,000. Working capital for the first 3–6 months is $40,000–$100,000, and that is the number people underfund.

Liquidity requirement. Expect the franchisor to want $80,000–$160,000 liquid on top of financing. Your own reserve should be higher than the minimum — model 9 months of full operating cost, not 3.

Ongoing fees. Royalty in the 6%–7% of gross range, plus a marketing or brand fund contribution around 1%–2%. On a $1.2 million unit that is $84,000–$108,000 a year going to the franchisor before you count local advertising you fund yourself.

Occupancy. The prototype calls for roughly 1,200–1,800 square feet with 4–6 exam rooms, though older or larger builds run to 2,500. Medical-office space in a desirable suburban corridor rents at $22–$35 per square foot triple net. A 1,500-square-foot clinic therefore costs $33,000–$52,000 a year in base rent, and you should budget 3–6 months of that — $15,000–$26,000 — as pre-opening dead rent during build-out and licensing.

Patient pricing. Initial medical evaluation typically prices at $150–$300. Monthly supervision visits run $100–$250. Medication is either marked up 15%–30% over wholesale or bundled into a flat program fee of roughly $300–$600 per month covering visit plus prescription. Bundled pricing generally produces better retention and cleaner cash forecasting than à-la-carte.

Unit economics at a mature clinic. Take a $1.4 million gross as the working model. Medical and clinical labor absorbs roughly 35% ($490,000). Medications, supplies, and lab costs run about 20% ($280,000). Rent plus royalty together take about 16% ($224,000). Marketing, administration, insurance, and software take about 14% ($196,000). What remains is roughly $210,000 in owner earnings. Move any of those percentages by three points and owner earnings swing $40,000.

System size and concentration. The system sits at roughly 120–140 open units nationwide, heavily weighted toward Florida, Texas, Georgia, and the Carolinas. That concentration matters two ways: in those states you get denser franchisee peer support and faster answers, but you also face the highest odds of a nearby unit cannibalizing 15%–25% of the patients a virgin territory would deliver.

Timeline. From signed agreement to open doors is typically 6–12 months. Faster openings are almost always second-generation medical space. Slower ones are almost always medical-board licensing or prescriber recruitment.

Risks, edge cases, and failure modes

The medical director bottleneck. This is the number-one cause of delayed openings in this category. Every clinic needs a licensed MD or DO as prescriber of record and supervising physician. Many states require on-site presence of 4–8 hours weekly. You are competing for part-time physician hours against urgent care, telemedicine startups, hospital systems, and med-spas. The mitigation is structural: identify two or three local physicians who already prescribe GLP-1s in private practice and offer a 10%–15% equity stake in the clinic entity in exchange for medical director duties. That aligns their incentive with your patient count and typically cuts your cash salary burden by 40%–60%. Get a signed, dated agreement — not a handshake — before you sign the lease.

State scope-of-practice divergence. In roughly 30 states, NPs or PAs can prescribe under a collaborative agreement with a supervising physician. In Florida, Texas, and Arizona this makes the NP-led model viable and cheap. In California and New York you will need hands-on MD involvement and your labor line will be materially higher. Corporate-practice-of-medicine doctrine also varies: in several states a non-clinician cannot own the professional entity that employs the physician, and you will need a management-services-organization structure where your franchise entity contracts with a physician-owned PC. Budget $8,000–$20,000 in healthcare-transactional legal fees to structure this correctly. Getting it wrong is not a paperwork problem — it can void your ability to bill.

Compounded semaglutide undercutting your program price. Compounding pharmacies have offered semaglutide at roughly $150–$300 monthly out of pocket, well under a bundled clinic program. Some patients will bypass supervision entirely. Two things blunt this: FDA posture toward compounding tightens when branded shortage conditions resolve, and most insurers that cover any portion of GLP-1 therapy require documented physician-supervised treatment. Your defense is to sell the supervision — bloodwork, titration, side-effect management, comorbidity screening — not the molecule. If your value proposition is "we sell the drug," a website will beat you on price every quarter.

Territory that looks exclusive but isn't competitively. Run the actual search before you sign. Map every med-spa, telehealth prescriber with local advertising, hospital-affiliated weight management program, and primary care practice offering GLP-1s within a 15-minute drive. If you find three or more Medi-Weightloss units within 10 miles, or a metro like Tampa, Orlando, or Atlanta already carrying dense coverage, discount your patient-count model by 15%–25%.

Insurance and reimbursement volatility. GLP-1 coverage policy is genuinely unsettled — employer plans have added and dropped coverage repeatedly. Build your model on cash-pay patients. If insurance reimbursement expands, treat it as upside; if you built the model assuming coverage and it contracts, you have a structural hole.

Retention cliff at goal weight. Patients who reach target weight often stop paying. A clinic that has no maintenance program watches 30%–40% of its panel churn annually and spends its marketing budget replacing revenue rather than adding it. Build a maintenance tier — lower-frequency visits, lower price point, continued monitoring — before you need it.

Resale versus new build. Buying an existing unit removes the two worst risks: you inherit a functioning prescriber relationship and a licensed, built-out space. Ask for three years of P&Ls, the current active-patient count, the GLP-1 mix percentage, the medical director's contract and notice provisions, and remaining lease term. The single most important diligence question on a resale is whether the medical director stays after closing — if that relationship is the seller's personal one, you may be buying an empty clinic at a full price.

A practical rollout plan

Sequence matters more than speed here. The plan below deliberately puts prescriber recruitment before real estate commitment, which is the inverse of how most franchise buyers run it — and the reason most of them slip their opening.

Days 1–20 — Document work. Get the 2026 FDD and read Items 5, 6, 7, 19, and 20 in full. Item 19 is the financial performance representation: note what it actually discloses (gross revenue tiers, cohort definitions, how many units are included) and what it omits. Item 20 tables show openings, closures, transfers, and terminations over three years — a rising transfer or termination count in a specific state is a signal worth chasing. Pull your state's medical board rules on physician supervision, NP prescriptive authority, and corporate practice of medicine.

Days 21–45 — Franchisee validation. Call at least eight current owners, including at least two who opened in the last 24 months and at least two in Item 20's transfer or closure lists if you can reach them. Ask specifically: what percentage of your patients are on a GLP-1 protocol, what do you pay your medical director and how did you find them, how long from signing to opening, what was your actual month-12 gross versus your pro forma, and what is your annual patient churn.

Days 46–70 — Prescriber and structure first. Before you sign any lease. Identify and get a signed letter of intent from a medical director candidate. Engage healthcare counsel to structure the entity correctly for your state. Confirm malpractice coverage availability and cost for the model you are running.

Days 71–95 — Market and site. Now do the territory analysis and site selection. Prioritize second-generation medical space. Negotiate a rent-abatement clause tied to your certificate of occupancy date, not to lease execution — this is the single highest-value lease term you can win and it protects you against exactly the failure mode above.

Days 96–140 — Build, license, staff. Run build-out, medical board licensing, EMR configuration, and clinical hiring in parallel. Begin pre-opening marketing at roughly day 110 so you open with a waitlist rather than an empty schedule.

Days 141–180 — Open and load. Open the clinic, drive patient acquisition hard, and track two numbers weekly: new patient starts and GLP-1 protocol percentage. If GLP-1 mix is under 40% by month three, your intake process or your pricing is wrong.

Related questions

Is it cheaper to buy an existing Medi-Weightloss clinic than to open a new one?

Often yes on risk, not always on price. A resale removes build-out overruns and prescriber-recruitment delay, but you pay for the established patient panel. Verify the medical director transfers with the business — that relationship is frequently the seller's personal one.

Can I own a Medi-Weightloss franchise without being a physician?

Yes in most states, with a medical director employed or contracted as prescriber of record. Several states' corporate-practice-of-medicine rules require a management-services structure where your entity contracts with a physician-owned professional corporation. Use healthcare counsel to structure it.

How much working capital should I actually hold beyond the FDD minimum?

Model nine months of full fixed cost — rent, prescriber, clinical salaries, royalty, insurance — not the three-to-six months typically listed. Ramp to break-even patient count commonly takes longer than pro formas assume, and underfunded reserves force premature marketing cuts.

Do GLP-1 telehealth companies make a physical clinic obsolete?

No, but they cap your pricing power. Telehealth wins on convenience and price for simple cases. Physical clinics win on bloodwork, comorbidity screening, side-effect management, and insurance documentation. Sell the supervision, not the medication.

What single diligence question predicts the most about a given territory?

Ask existing owners in the state what percentage of new patients start on a GLP-1 protocol. Under 40% signals either a slow-adapting market or an intake process that isn't converting. The strongest 2025–2026 units run 55%–70%.

FAQ

What is the total investment to open a Medi-Weightloss franchise?

Item 7 in the 2026 FDD puts total initial investment at roughly $200,000 to $450,000, including a franchise fee around $40,000. The spread is driven mostly by build-out: second-generation medical space with existing plumbing and medical HVAC can land near the bottom of the range, while a raw retail shell pushes you toward the top. Add working capital beyond the stated minimum.

How much does a Medi-Weightloss owner actually earn?

Mature clinics gross roughly $700,000 to $2,000,000 annually, with owner earnings commonly in the $120,000 to $350,000 range. The variance is driven primarily by prescriber cost as a percentage of gross and by GLP-1 patient mix. An owner running an NP-led model in a permissive state with a 60% medication mix will sit far above an owner carrying a full-time physician against a coaching-heavy panel.

What are the ongoing fees?

Royalty runs approximately 6% to 7% of gross revenue, with a marketing or brand fund contribution of roughly 1% to 2% on top. On a $1.2 million unit that is $84,000 to $108,000 annually before any local advertising you fund separately. Confirm exact percentages and any minimum-royalty provisions in your own franchise agreement — they can differ from the FDD summary.

How long does it take to open?

Typically 6 to 12 months from signed agreement to open doors. The fastest openings are almost always second-generation medical space with an already-recruited medical director. The slowest are stalled on state medical board licensing or prescriber recruitment. Recruiting your prescriber before signing a lease is the highest-leverage thing you can do to compress the timeline.

Are GLP-1 drugs a threat or an advantage for this model?

An advantage, structurally. Because Medi-Weightloss operates as a medical clinic rather than a coaching program, it can prescribe and manage semaglutide and tirzepatide directly. That converts a market disruption that damaged meal-replacement and coaching-only concepts into a recurring revenue stream — GLP-1 patients return every four to six weeks for titration and monitoring, generating far more annual revenue per patient than a non-medication client.

What is the biggest reason these clinics underperform?

Prescriber economics. A clinic that cannot recruit a medical director opens late and burns reserves on empty rent; a clinic that overpays for a full-time physician relative to its patient volume never clears meaningful owner comp. Solve staffing structure — equity participation, NP-led models where state law allows — before you commit capital to real estate.

Sources

• https://www.ftc.gov/business-guidance/resources/franchise-rule-compliance-guide
• https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss
• https://www.aanp.org/advocacy/state/state-practice-environment
• https://www.cdc.gov/obesity/data/adult.html
• https://www.franchise.org/
• https://www.sba.gov/funding-programs/loans/7a-loans
• https://www.entrepreneur.com/franchises/directory
• https://www.ama-assn.org/practice-management/private-practices/corporate-practice-medicine
• https://www.hhs.gov/hipaa/for-professionals/index.html

Related on PULSE

• [How long does it take to open a franchise and break even in 2027?](/knowledge/fr1104)
• [Should I open or buy a Tommy Gun's Original Barbershop franchise in 2027?](/knowledge/fr1095)
• [Should I open or buy a Painting with a Twist franchise in 2027?](/knowledge/fr1058)
• [Should I open or buy a Restore Hyper Wellness franchise in 2027?](/knowledge/fr1071)
• [Should I open or buy an Ideal Image franchise in 2027?](/knowledge/fr1082)